Author

Fangzhou Wu

0 works0 citationsORCID

Recent research

Health & Medicine
Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist
ABSTRACT Aims This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors....
Diabetes Obesity and Metabolism2026-09-200 citationsDOI